Immuno-Oncology Patents

Immuno-oncology IO patents cover PD-1/PD-L1 checkpoint inhibitor antibody innovations; CTLA-4 inhibitor innovations; CAR-T cell therapy constructs and manufacturing; bispecific antibody engager innovations; and TIL tumor-infiltrating lymphocyte adoptive cell therapy innovations — with IP held by the major pharmaceutical and biotech companies as well as academic institutions that pioneered checkpoint blockade: MAJOR IO PATENT HOLDERS: BMS AND ONO PHARMACEUTICAL: 500+; specific PD-1 checkpoint (specific specific nivolumab anti-PD-1: specific specific human IgG4 from specific specific S228P hinge substitution Fc silent at specific specific reduced Fc receptor binding from specific specific reduced ADCC/CDC from specific specific complete response CR >3 years melanoma NSCLC from specific specific PD-L1 TPS ≥1% indication from specific specific 5-year OS 26% vs. specific specific chemotherapy 5% in specific specific CheckMate-067 melanoma from specific specific BMS (CTLA-4 ipilimumab) + specific specific nivolumab combination from specific specific dual checkpoint blockade); MERCK: 500+; specific PD-1 biomarker (specific specific pembrolizumab Keytruda anti-PD-1: specific specific humanized IgG4 κ from specific specific TMB tumor mutational burden biomarker from specific specific TMB-H ≥10 mut/Mb from specific specific MSI-H microsatellite instability-high from specific specific CPS combined positive score TPS+IC from specific specific tumor-agnostic approval FDA 2020 from specific specific 10 tumor types TMB-H + specific specific dMMR MMR-deficient + specific specific MSI-H from specific specific anti-PD-1 $27B+ annual revenue 2024 from specific specific KEYNOTE-001 NSCLC TPS ≥50% first-line 45% 5-year OS); NOVARTIS/UNIVERSITY OF PENNSYLVANIA: 200+; specific CAR-T (specific specific Kymriah tisagenlecleucel CTL019: specific specific CD19 4-1BB CD3ζ CAR construct from specific specific lentiviral vector transduction from specific specific patient T-cell apheresis from specific specific 10-day manufacturing at specific specific 8.5×10^8 CAR-T cells from specific specific bridging therapy optional from specific specific 1-3×10^8 cells/kg dosing from specific specific CRS cytokine release syndrome grade ≥3 13% from specific specific CR 52% DLBCL large B-cell lymphoma from specific specific ALL pediatric CR 81% from specific specific FDA 2017 first CAR-T approval; GILEAD/KITE: 200+; FMC63 CD28 CD3ζ axi-cel CD19 CAR-T DLBCL ORR 72% CRS grade ≥3 11% FDA 2017; ASTRAZENECA; ROCHE/GENENTECH; PFIZER; ELI LILLY: combined 5,000+ IO IP.

Checkpoint inhibitor antibody engineering innovations for improved PD-1/PD-L1 binding or combination pharmacology; CAR-T cell therapy construct innovations for improved efficacy and reduced toxicity; and bispecific antibody innovations for T-cell engaging tumor targeting represent three core IO patent domains: CHECKPOINT INHIBITOR ANTIBODY PATENTS: BMS; MERCK; ROCHE/GENENTECH; ASTRAZENECA; REGENERON; INCYTE: specific checkpoint antibody (specific specific atezolizumab anti-PD-L1: specific specific human IgG1 N297A aglycosyl Fc engineering from specific specific glycosylation removal at specific specific Asn297 for specific specific FcγR ADCC completely abrogated from specific specific PD-L1 IC50 0.4 nM from specific specific Roche Genentech patent from specific specific bladder NSCLC triple-negative breast TNBC from specific specific PD-L1 IC1/2/3 CPS scoring from specific specific IMvigor211 urothelial; specific specific durvalumab+tremelimumab combination: specific specific anti-PD-L1+anti-CTLA-4 from specific specific hepatocellular NSCLC mesothelioma from specific specific POSEIDON trial NSCLC 1st line + specific specific MYSTIC from specific specific Fc gamma receptor silent from specific specific 5-year OS 15.7% vs. specific specific 10.3% platinum chemo for specific specific unresectable hepatocellular carcinoma HCC); CAR-T CONSTRUCT PATENTS: NOVARTIS/PENN; GILEAD/KITE; BRISTOL-MYERS SQUIBB CELGENE; JANSSEN; BLUEBIRD BIO: specific CAR-T (specific specific BCMA CAR-T ide-cel: specific specific BCMA B-cell maturation antigen from specific specific 4-1BB CD3ζ CAR from specific specific lentiviral transduction from specific specific 3×10^6 cells/kg from specific specific CR 39% relapsed/refractory multiple myeloma RRMM from specific specific BMS ide-cel from specific specific bb2121 from specific specific RRMM >3 prior lines; specific specific GPRC5D CAR-T talquetamab: specific specific GPRC5D G-protein coupled receptor class C group 5 member D from specific specific CD3ζ bispecific + specific specific PD-1 blockade from specific specific 73% ORR RRMM from specific specific nail/skin toxicity GPRC5D receptor keratinocyte); BISPECIFIC ANTIBODY PATENTS: AMGEN; JANSSEN (J&J); ABBVIE; GENENTECH; PFIZER; MERUS: specific bispecific (specific specific blinatumomab BiTE: specific specific anti-CD19 scFv+anti-CD3 scFv from specific specific 55 kDa no Fc from specific specific 2 nM CD19 KD from specific specific 300 pM CD3 KD from specific specific T-cell redirect at specific specific 1:100,000 E:T ratio effective from specific specific 39% CRi ALL Ph-neg from specific specific Amgen MT103 patent from specific specific continuous IV infusion 28-day from specific specific 5 μg/m²/day→15 μg/m²/day step-up for specific specific CRS mitigation).

TIL tumor-infiltrating lymphocyte adoptive cell therapy innovations for solid tumor treatment; cancer vaccine innovations including mRNA neoantigen vaccine; and innate immune agonist and STING pathway innovations represent three additional IO patent domains: TIL THERAPY PATENTS: IOVANCE BIOTHERAPEUTICS; MOFFITT CANCER CENTER; INSTIL BIO; ACHILLES THERAPEUTICS; NIH/NCI: specific TIL therapy (specific specific TIL manufacturing: specific specific tumor resection fragment from specific specific rapid expansion protocol REP from specific specific IL-2 6,000 IU/mL from specific specific anti-CD3 OKT3 30 ng/mL from specific specific irradiated feeder PBMC 200:1 from specific specific 5,000-fold expansion 14 days from specific specific infusion product 10^9-10^11 TIL cells from specific specific conditioning lymphodepletion Cy/Flu from specific specific CR 20-35% metastatic melanoma uveal from specific specific Iovance LN-145 afami-cel FDA 2024 first TIL therapy approval from specific specific 31.5% ORR cervical cancer from specific specific multi-tumor type TIL from specific specific TCR tumor-specific clone enrichment); CANCER VACCINE PATENTS: BIONTECH; MODERNA; NEON THERAPEUTICS (BMS); NEOANTIGEN AI: specific cancer vaccine (specific specific mRNA neoantigen vaccine: specific specific tumor WES whole exome sequencing from specific specific RNA-seq tumor vs. normal from specific specific neoantigens somatic mutation 10-20 per tumor at specific specific MHC-I/II predicted binding affinity <500 nM from specific specific BioNTech iNeST individualized neoantigen specific immunotherapy from specific specific RNA lipid nanoparticle LNP formulation from specific specific 20 neoantigen peptide mRNA cocktail from specific specific BNT122 mRNA-4157 Phase 2 melanoma from specific specific Moderna+Merck combination pembrolizumab from specific specific 44% reduction recurrence vs. specific specific pembrolizumab alone in specific specific KEYNOTE-942 Phase 2b); INNATE IMMUNE/STING PATENTS: ADURO/INCYTE; MERCK; ASTRAZENECA INNATE; SPRING BIOSCIENCE; GSK: specific innate IO (specific specific STING agonist: specific specific cyclic dinucleotide CDN from specific specific cGAMP 2&apos;3&apos;-cGAMP from specific specific STING stimulator of interferon genes from specific specific dsDNA sensor cGAS-STING pathway from specific specific IRF3 TBK1 phosphorylation from specific specific IFN-β Type I interferon from specific specific >10 nM EC50 IFN-β induction from specific specific ADU-S100 intratumoral IT from specific specific ADURO patent from specific specific Phase 1 IT injection from specific specific combination PD-1 from specific specific tumor microenvironment TME reprogramming from specific specific T-cell priming vs. specific specific cold tumor).

IO startup IP strategy must navigate extremely complex patent landscapes including the foundational PD-1/PD-L1 checkpoint patents (BMS/Ono vs. Merck dispute settled for $625M in 2017); understand the aggressive patenting environment in CAR-T (Novartis/Penn vs. Juno/BMS $1.2B settlement); recognize that biomarker patents co-invented with clinical trials create uniquely strong compound+method-of-treatment IP; and appreciate the difference between foundational pathway IP (typically held by universities/foundations) and optimized therapeutic agent IP (held by pharmaceutical/biotech companies): IO STARTUP IP STRATEGY: UNDERSTAND THE IO IP LANDSCAPE: PD-1/PD-L1 CHECKPOINT IP IS SETTLED BUT FOUNDATIONAL: The BMS/Ono vs. Merck PD-1 patent dispute was the largest biotech IP litigation in history at time of settlement ($625M 2017) — the core PD-1 antagonist antibody composition claims are held by BMS/Ono with cross-licenses; any novel anti-PD-1 or anti-PD-L1 antibody must be differentiated by specific epitope, Fc engineering, or combination with novel targets; CTLA-4 ipilimumab is BMS-foundational; next-generation checkpoint targets LAG-3, TIM-3, TIGIT represent more accessible IP; CAR-T IP IS HEAVILY CONTESTED BETWEEN NOVARTIS/PENN AND KITE/JUNO: The CAR-T space had the largest IP dispute (Novartis/Penn CD19 4-1BB vs. Kite/BMS CD3ζ CD28 $1.2B settlement) — any novel CAR-T construct must carefully distinguish from both 4-1BB CD3ζ and CD28 CD3ζ combinations; novel co-stimulatory domains (OX40, ICOS, DAP12), novel tumor antigens (GPRC5D, FcRH5, TROP2), and allogeneic CAR-T represent whitespace; BISPECIFIC ANTIBODY FORMAT IP IS INCREASINGLY IMPORTANT: BiTE (Amgen), DART (MacroGenics), Triomab (Trion), DuoBody (Genmab) and other bispecific formats are each IP-protected — format choice must include FTO analysis; mRNA NEOANTIGEN VACCINE IS EMERGING WHITESPACE: BioNTech and Moderna&apos;s mRNA neoantigen vaccine clinical programs represent a relatively new area — IP is in formation, neoantigen prediction algorithm+delivery IP combination represents genuine startup opportunity; WHEN TO PATENT IN IO: NOVEL ANTIBODY TARGETING NEW CHECKPOINT WITH DEMONSTRATED PRECLINICAL ACTIVITY: specific novel antibody construct (specific specific target antigen + specific specific antibody format + specific specific Fc engineering) with specific measured preclinical activity (specific specific in vitro T-cell activation assay nM EC50, specific specific mouse tumor model tumor growth inhibition %, specific specific TGI % at specific specific dose, specific specific PK parameters t1/2, Cmax, AUC) vs. specific specific pembrolizumab or specific specific nivolumab at specific specific same tumor model — mechanism of action differentiation + preclinical efficacy data are essential for novel IO antibody IP; NOVEL CAR-T CONSTRUCT WITH MEASURED EFFICACY AND REDUCED TOXICITY: specific novel CAR-T construct (specific specific antigen binding domain + specific specific co-stimulatory domain + specific specific Fc or hinge + specific specific logic gate if multi-antigen) with specific measured performance (specific specific in vitro tumor kill EC50, specific specific cytokine secretion profile TNF-α/IFN-γ/IL-2 pg/mL at specific specific E:T ratio, specific specific CRS marker IL-6/ferritin in specific specific mouse model at specific specific specific dose, specific specific in vivo tumor regression % and durability days) vs. specific specific 4-1BB CD3ζ CTL019 or specific specific CD28 CD3ζ axi-cel benchmark — efficacy+toxicity margin vs. approved CAR-T benchmarks is key to both patent differentiation and regulatory strategy; NOVEL BIOMARKER WITH VALIDATED PREDICTIVE POWER: specific novel IO biomarker (specific specific measurement method + specific specific patient selection criterion) with specific measured predictive performance (specific specific HR hazard ratio for OS/PFS, specific specific P-value, specific specific C-statistic for biomarker-selected vs. unselected population) validated in specific specific Phase 2/3 clinical trial co-enrolled biomarker cohort — companion diagnostic CD co-development with a novel IO biomarker creates the strongest possible therapeutic IP (composition patent + biomarker patent + method-of-treatment patent) and aligns with FDA regulatory strategy; KEY FTO CHECKLIST: BMS/Ono nivolumab human IgG4 S228P Fc silent PD-1 antagonist CR >3yr 5-yr OS 26% melanoma NSCLC PD-L1 TPS≥1% CheckMate; Merck pembrolizumab humanized IgG4 κ Keytruda TMB-H ≥10 mut/Mb MSI-H CPS dMMR tumor-agnostic $27B; Novartis/Penn Kymriah CD19 4-1BB CD3ζ lentiviral REP 10-day manufacturing CRS grade≥3 13% CR 52% DLBCL ALL 81% FDA 2017; Kite/Gilead axi-cel FMC63 CD28 CD3ζ CD19 DLBCL ORR 72% FDA 2017; Amgen blinatumomab BiTE CD19+CD3 scFv 55 kDa no Fc 2 nM/300 pM CRi ALL 39% continuous IV; BMS ide-cel BCMA 4-1BB CD3ζ lentiviral CR 39% RRMM ≥3 prior lines; BioNTech/Moderna BNT122 mRNA-4157 neoantigen LNP 20 mRNA cocktail 44% recurrence reduction KEYNOTE-942 Phase 2b; Aduro ADU-S100 STING cGAMP IT Phase 1 TME reprogramming.